M&A · Healthcare · Buyer's industry: In Vitro & In Vivo Diagnostic Substances
Lantheus Holdings, Inc. to acquire Cerveau Technologies
Announced Feb 6, 2023 · Closed Feb 6, 2023 · Private target
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationNot disclosed
Transaction
- Acquirer
- Lantheus Holdings, Inc. (LNTH)
- Target
- Cerveau Technologies
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Feb 6, 2023
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- Not disclosed
- To the target
- Not disclosed
Classification
- Sector
- Healthcare
- Buyer's industry
- In Vitro & In Vivo Diagnostic Substances